An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)

CompletedOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Macular Edema
Interventions
DRUG

dexamethasone 700 ㎍ intravitreal implant

Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Diabetic Macular Edema. All decisions regarding treatment are made at the sole discretion of the treating physician in accordance with their usual practices.

Trial Locations (18)

11201

Long Island Vitreoretinal Consultants - Long Island Retina - Hauppauge, Great Neck

19109

Mid Atlantic Retina, Philadelphia

46290

Raj Maturi, MD PC, Indianapolis

47150

John-Kenyon American Eye Institute, New Albany

48073

Associated Retina Consultants, Royal Oak

60426

Illinois Retina Associates, Harvey

63017

Lifelong Vision Foundation, Chesterfield

69686

Associated Retinal Consultants, PC, Traverse City

76012

Texas Retina Associates, Arlington, Arlington

78240

Medical Center Ophthalmology Associates, San Antonio

78503

Valley Retina Institute, P.A., McAllen

80230

Colorado Retina Associates, Denver

85014

Retinal Consultants of Phoenix, Phoenix

92705

Orange Co Retina Medical Group, Santa Ana

94109

West Coast Retina, San Francisco

94598

Bay Area Retina Associates, Walnut Creek

03801

Eyesight Ophthalmic Services, Portsmouth

08901

New Jersey Retina, New Brunswick

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY